ASH 2023 Myeloma Recap with Dr. Ben Derman
Вставка
- Опубліковано 18 вер 2024
- In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode:
First, we will focus on a few abstracts in precursor states, MGUS.
1. New diagnostic criteria for light chain MGUS (IStopMM):
ash.confex.com...
ash.confex.com...
2. PERSEUS Trial-Dara-VRD vs VRD in newly diagnosed transplant-eligible myeloma:
ash.confex.com...
3. ISKIA trial: Isa-KRD vs KRD in newly diagnosed transplant-eligible myeloma:
ash.confex.com...
4. Phase 1/2 study for Daratumumab-Venetoclax-Dexamethasone in early relapsed t(11;14) myeloma:
ash.confex.com...
5. GMMG Relapse Trial (Long-term follow-up data from randomized controlled trial of salvage transplant in myeloma)
ash.confex.com...
6. Overall survival results of KarMMa-3 trial
ash.confex.com...
7. GEM2017FIT Trial: Dara-KRd vs KRd vs VMP-RD in non-transplant eligible patients:
ash.confex.com...
Post bone marrow transplant in August 2022 I started Lenalidomide on its own as maintenance therapy.
Started DVTD. Within weeks suffered peripheral neuropathy. Velcade and Thalidomide stopped. Daratumumab and Dexamethasone took my Paraprotein from 79% to 0%. Daratumumab is a wonder drug.
will be great to have people discuss Manifest-2 and Transform-1